Baseline differences between patients with non-incidental and incidental diagnosis
| . | All . | Nonincidental . | Incidental . | P . |
|---|---|---|---|---|
| No. (%)a | 114 (100) | 94 (82.5) | 20 (17.5) | |
| Age at diagnosis, y; median (IQR) | 71.7 (5.4) | 69.9 (8.0) | 72.8 (8.8) | .05 |
| > 75, n (%) | 34 (28.8) | 24 (55.5) | 10 (50.0) | .10 |
| > 80, n (%) | 9 (7.6%) | 6 (6.4) | 3 (15.0) | .19 |
| Male sex, n (%) | 34 (28.8) | 25 (26.6) | 9 (45.0) | .17 |
| SBD, mo; median (IQR) | 48 (100) | 48 (100) | 0 (85) | .03 |
| GH, ng/mL; median (IQR)b | 7.23 (11.6) | 7 (11.1) | 9.7 (17.7) | .13 |
| IGF-1, ng/mL; median (IQR) | 573.0 (321.8) | 556.0 (312.0) | 591.9 (386.0) | .72 |
| IGF-1 (×ULN) | 2.6 (1.8) | 2.6 (1.5) | 2.9 (2.3) | .18 |
| Max diameter, mm; median (IQR)b | 12.0 (6.0) | 11 (6.0) | 14 (6.8) | .22 |
| Macroadenoma, n (%) | 81 (68.6) | 31 (73.8) | 50 (65.8) | .37 |
| Extrasellar, n (%)c | 50 (48.1) | 39 (47.0) | 11 (55.0) | 1.00 |
| Chiasm compression, n (%)c | 15 (14.3) | 12 (14.3) | 3 (15.0) | .45 |
| Cavernous sinus invasion, n (%)b | 49 (46.7) | 32 (37.7) | 17 (85.0) | .01 |
| . | All . | Nonincidental . | Incidental . | P . |
|---|---|---|---|---|
| No. (%)a | 114 (100) | 94 (82.5) | 20 (17.5) | |
| Age at diagnosis, y; median (IQR) | 71.7 (5.4) | 69.9 (8.0) | 72.8 (8.8) | .05 |
| > 75, n (%) | 34 (28.8) | 24 (55.5) | 10 (50.0) | .10 |
| > 80, n (%) | 9 (7.6%) | 6 (6.4) | 3 (15.0) | .19 |
| Male sex, n (%) | 34 (28.8) | 25 (26.6) | 9 (45.0) | .17 |
| SBD, mo; median (IQR) | 48 (100) | 48 (100) | 0 (85) | .03 |
| GH, ng/mL; median (IQR)b | 7.23 (11.6) | 7 (11.1) | 9.7 (17.7) | .13 |
| IGF-1, ng/mL; median (IQR) | 573.0 (321.8) | 556.0 (312.0) | 591.9 (386.0) | .72 |
| IGF-1 (×ULN) | 2.6 (1.8) | 2.6 (1.5) | 2.9 (2.3) | .18 |
| Max diameter, mm; median (IQR)b | 12.0 (6.0) | 11 (6.0) | 14 (6.8) | .22 |
| Macroadenoma, n (%) | 81 (68.6) | 31 (73.8) | 50 (65.8) | .37 |
| Extrasellar, n (%)c | 50 (48.1) | 39 (47.0) | 11 (55.0) | 1.00 |
| Chiasm compression, n (%)c | 15 (14.3) | 12 (14.3) | 3 (15.0) | .45 |
| Cavernous sinus invasion, n (%)b | 49 (46.7) | 32 (37.7) | 17 (85.0) | .01 |
Abbreviations: GH, growth hormone; IGF-1, insulin-like growth factor 1; IQR, interquartile range; max, maximum; SBD, symptoms before diagnosis; ULN, upper limit of normal.
Reported in 114 patients.
Reported in 110 patients.
Reported in 105 patients.
Baseline differences between patients with non-incidental and incidental diagnosis
| . | All . | Nonincidental . | Incidental . | P . |
|---|---|---|---|---|
| No. (%)a | 114 (100) | 94 (82.5) | 20 (17.5) | |
| Age at diagnosis, y; median (IQR) | 71.7 (5.4) | 69.9 (8.0) | 72.8 (8.8) | .05 |
| > 75, n (%) | 34 (28.8) | 24 (55.5) | 10 (50.0) | .10 |
| > 80, n (%) | 9 (7.6%) | 6 (6.4) | 3 (15.0) | .19 |
| Male sex, n (%) | 34 (28.8) | 25 (26.6) | 9 (45.0) | .17 |
| SBD, mo; median (IQR) | 48 (100) | 48 (100) | 0 (85) | .03 |
| GH, ng/mL; median (IQR)b | 7.23 (11.6) | 7 (11.1) | 9.7 (17.7) | .13 |
| IGF-1, ng/mL; median (IQR) | 573.0 (321.8) | 556.0 (312.0) | 591.9 (386.0) | .72 |
| IGF-1 (×ULN) | 2.6 (1.8) | 2.6 (1.5) | 2.9 (2.3) | .18 |
| Max diameter, mm; median (IQR)b | 12.0 (6.0) | 11 (6.0) | 14 (6.8) | .22 |
| Macroadenoma, n (%) | 81 (68.6) | 31 (73.8) | 50 (65.8) | .37 |
| Extrasellar, n (%)c | 50 (48.1) | 39 (47.0) | 11 (55.0) | 1.00 |
| Chiasm compression, n (%)c | 15 (14.3) | 12 (14.3) | 3 (15.0) | .45 |
| Cavernous sinus invasion, n (%)b | 49 (46.7) | 32 (37.7) | 17 (85.0) | .01 |
| . | All . | Nonincidental . | Incidental . | P . |
|---|---|---|---|---|
| No. (%)a | 114 (100) | 94 (82.5) | 20 (17.5) | |
| Age at diagnosis, y; median (IQR) | 71.7 (5.4) | 69.9 (8.0) | 72.8 (8.8) | .05 |
| > 75, n (%) | 34 (28.8) | 24 (55.5) | 10 (50.0) | .10 |
| > 80, n (%) | 9 (7.6%) | 6 (6.4) | 3 (15.0) | .19 |
| Male sex, n (%) | 34 (28.8) | 25 (26.6) | 9 (45.0) | .17 |
| SBD, mo; median (IQR) | 48 (100) | 48 (100) | 0 (85) | .03 |
| GH, ng/mL; median (IQR)b | 7.23 (11.6) | 7 (11.1) | 9.7 (17.7) | .13 |
| IGF-1, ng/mL; median (IQR) | 573.0 (321.8) | 556.0 (312.0) | 591.9 (386.0) | .72 |
| IGF-1 (×ULN) | 2.6 (1.8) | 2.6 (1.5) | 2.9 (2.3) | .18 |
| Max diameter, mm; median (IQR)b | 12.0 (6.0) | 11 (6.0) | 14 (6.8) | .22 |
| Macroadenoma, n (%) | 81 (68.6) | 31 (73.8) | 50 (65.8) | .37 |
| Extrasellar, n (%)c | 50 (48.1) | 39 (47.0) | 11 (55.0) | 1.00 |
| Chiasm compression, n (%)c | 15 (14.3) | 12 (14.3) | 3 (15.0) | .45 |
| Cavernous sinus invasion, n (%)b | 49 (46.7) | 32 (37.7) | 17 (85.0) | .01 |
Abbreviations: GH, growth hormone; IGF-1, insulin-like growth factor 1; IQR, interquartile range; max, maximum; SBD, symptoms before diagnosis; ULN, upper limit of normal.
Reported in 114 patients.
Reported in 110 patients.
Reported in 105 patients.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
